Summa Equity to sell HyTest to Mindray for EUR 545 million

Avance advises Summa Equity in the sale of HyTest, a leading developer and producer of high-performance antibodies and antigens, to Mindray, a leading global medical technology company, for total consideration of approximately EUR 545 million.

Finland-based HyTest was founded in 1994 and has currently around 130 employees. HyTest’s products cover over 20 disease groups and yearly provides antibodies and antigens for in vitro diagnostic (IVD) tests run on over 300 million patients globally.

The transaction is subject to customary regulatory approvals. Completion of the transaction is expected in the second half of the year.